PCSK9 Inhibitors: The Evolving Future
Health Science Reports · 2024-11 · 7 (11)
DOI: 10.1002/hsr2.70174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 30.10.2024. Verfasst von Bijay Mukesh Jeswani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine GCS Medical College, Hospital & Research Centre Ahmedabad India. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing LDL receptor activity, promoting clearance of LDL‐C from the bloodstream. Over the years, PCSK9 inhibitors have been explored as adjunct therapies to statins or as monotherapy in high‐risk cardiovascular patients.
Aim
This review aims to provide an updated perspective on PCSK9 inhibitors, assessing their clinical efficacy, safety, and significance, especially in light of recent clinical trials.
Methods
The review examines the role of PCSK9 in cholesterol regulation and summarizes the results of major cardiovascular trials, including FOURIER, SPIRE‐1, SPIRE‐2, and ODYSSEY Outcomes. It also discusses emerging treatments like small interfering RNA (siRNA) therapies and evaluates PCSK9 inhibitor effects on LDL‐C and lipoprotein(a) levels.
Results
Clinical trials have shown PCSK9 inhibitors reduce LDL‐C by up to 60%. In the FOURIER trial, evolocumab reduced LDL‐C by 59% and major cardiovascular events by 15%–20%. The SPIRE‐2 trial, despite early termination, showed a 21% risk reduction in the primary composite endpoint with bococizumab. The ODYSSEY Outcomes trial reported a 57% LDL‐C reduction with alirocumab, alongside a 15% reduction in adverse events. Emerging treatments like Inclisiran offer long‐term LDL‐C control with fewer doses. PCSK9 inhibitors are generally well‐tolerated, with the most common side effect being injection site reactions.
Conclusion
PCSK9 inhibitors significantly lower LDL‐C and reduce cardiovascular events, offering promising therapies for high‐risk patients, including those with familial hypercholesterolemia (FH) and those who cannot tolerate statins. Future research will focus on optimizing these inhibitors, integrating complementary therapies, and exploring gene‐editing technologies to improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine GCS Medical College, Hospital & Research Centre Ahmedabad India.
- Department of Medicine B.J. Governement Medical College Pune India.
- Department of Medicine Dr. Sampurnanand Medical College Jodhpur Rajasthan India.
- Department of Medicine King Edward Medical University Lahore Pakistan.
- Department of Medicine Oli Health Magazine Organization, Research, and Education Kigali Rwanda.
- Cardiology, AdventHealth Orlando Orlando Florida USA.
ORCID-Profile: Bijay Mukesh Jeswani, Abubakar Nazir
Zitieren
APA
Jeswani, B. M., Sharma, S., Rathore, S. S., Nazir, A., Bhatheja, R., & Kapoor, K. (2024). PCSK9 Inhibitors: The Evolving Future. Health Science Reports, 7(11). https://doi.org/10.1002/hsr2.70174
Vancouver
Jeswani BM, Sharma S, Rathore SS, Nazir A, Bhatheja R, Kapoor K. PCSK9 Inhibitors: The Evolving Future. Health Science Reports. 2024;7(11). doi:10.1002/hsr2.70174
BibTeX
@article{Jeswani2024,
author = {Jeswani, Bijay Mukesh and Sharma, Shubhangi and Rathore, Sawai Singh and Nazir, Abubakar and Bhatheja, Rohit and Kapoor, Kapil},
title = {PCSK9 Inhibitors: The Evolving Future},
journal = {Health Science Reports},
year = {2024},
volume = {7},
number = {11},
doi = {10.1002/hsr2.70174}
}
EUVIMED